Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika

Andrade, Paulina; Gimblet-Ochieng, Ciara; Modirian, Faraz; Collins, Matthew H.; Cárdenas, Maritza; Katzelnick, Leah C.; Montoya, Magelda; Michlmayr, Daniela; Kuan, Guillermina; Balmaseda, Ángel; Coloma, Joséfina; Silva, Aravinda M. de; Harris, Eva

doi:10.1038/s41467-019-08845-3

Cited by 50 publications

(67 citation statements)

References 64 publications

(86 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study showed that cross-reactive ZIKV-primed CD4 + T cells 73 . On the other hand, we showed that naïve animals with DENV de novo response did not cross-neutralized ZIKV at all, which state that although similar, antigenic differences are sufficient to mount predominantly type-specific rather than crossreactive responses during a primary infection 50,55 .…”

Section: Higher Proportion Of Ifn-γ and Tnf-α Producing T Cells Beformentioning

confidence: 72%

Time elapsed between Zika and dengue virus infections affects antibody and T cell responses

Pérez-Guzmán

Pantoja

Serrano-Collazo

et al. 2019

Preprint

View full text Add to dashboard Cite

34The role of Zika virus (ZIKV) immunity on subsequent dengue virus (DENV) infections is 35 relevant to anticipate the dynamics of forthcoming DENV epidemics in areas with previous ZIKV 36 exposure. We study the effect of ZIKV infection with various strains on subsequent DENV 37 immune response after 10 and 2 months of ZIKV infection in rhesus macaques. Our results 38show that a subsequent DENV infection in animals with early-and middle-convalescent periods 39 to ZIKV do not promote an increase in DENV viremia nor pro-inflammatory status. Previous 40 ZIKV exposure increases the magnitude of the antibody and T cell responses against DENV, 41 and different time intervals between infections alter the magnitude and durability of such 42 responses-more after longer ZIKV pre-exposure. Collectively, we find no evidence of a 43 detrimental effect of ZIKV immunity in a subsequent DENV infection. This supports the 44 implementation of ZIKV vaccines that could also boost immunity against future DENV 45 epidemics. 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61Zika virus (ZIKV) is a re-emerging mosquito-borne Flavivirus that has captivated the 62 attention of the scientific community by its explosive spread in The Americas 1 , and severe 63 neurological sequelae following infection 2-4 . ZIKV established itself in tropical and sub-tropical 64 regions that are endemic to other closely-related flaviviruses such as dengue virus (DENV). 65Both viruses belong to the Flaviviridae family and are transmitted by Aedes spp. mosquitoes. 66DENV is a global public health threat, having two-thirds of world's population at risk of infection, 67 causing ~390 million infections annually 5,6 . DENV exists as four genetically similar but 68 antigenically different serotypes (DENV1-4) 7 . Exposure to one DENV serotype confers long-69 lived immunity against a homotypic secondary infection. However, secondary infection with a 70 heterologous serotype of DENV is the major risk factor to induce severe DENV disease [8][9][10] . 71Due to the antigenic similarities between DENV and ZIKV, concerns have been raised 72 regarding the impact of DENV-ZIKV cross-reactive immunity on the development of severe 73 clinical manifestations 11,12 . It has been demonstrated that DENV-immune sera from humans can 74 enhance ZIKV infection in vitro 13,14 , and in vivo in immune-deficient mouse models 15 . However, 75 recent results from our group and others have shown that previous flavivirus exposure-76including DENV-may have no detrimental impact on ZIKV infection in vivo in non-human 77 primates (NHP) 16,17 and humans 18 . Moreover, these studies and others suggest that previous 78 DENV immunity may play a protective role during ZIKV infection involving humoral and cellular 79 responses 19-23 . On the other hand, little is known about the opposite scenario, the role of a 80 previous ZIKV exposure on subsequent DENV infection, which is relevant to anticipate the 81 dynamics of forthcoming DENV epidemics. 82The recent ZIKV epidemic in the Americas resulted in t...

show abstract

Section: Higher Proportion Of Ifn-γ and Tnf-α Producing T Cells Beformentioning

confidence: 72%

Time elapsed between Zika and dengue virus infections affects antibody and T cell responses

Pérez-Guzmán

Pantoja

Serrano-Collazo

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Mouse studies have shown that Bmem responses to West Nile virus (WNV) retain the ability to engage variant viruses whereas antibody derived from LLPC is poorly able to inhibit variant virus (Purtha et al, 2011). Studies of human Zika and Dengue virus responses have shown that Bmem responses are more diverse than those of the serum (LLPC)-derived antibody (Andrade et al, 2019).…”

Section: Germinal Center Responsesmentioning

confidence: 99%

B Cell Responses: Cell Interaction Dynamics and Decisions

Cyster

Allen

2019

Cell

631

634

View full text Add to dashboard Cite

B cells and the antibodies they produce have a deeply penetrating influence on human physiology. Here, we review current understanding of how B cell responses are initiated; the different paths to generate short-and long-lived plasma cells, germinal center cells, and memory cells; and how each path impacts antibody diversity, selectivity, and affinity. We discuss how basic research is informing efforts to generate vaccines that induce broadly neutralizing antibodies against viral pathogens, revealing the special features associated with allergen-reactive IgE responses and uncovering the antibody-independent mechanisms by which B cells contribute to health and disease.

show abstract

“…Here, we described the development of an hAd5 ZIKV vaccine that encodes and expresses the full length prM and E structural proteins from ZIKV virus PRVABC59. Flavivirus E proteins are known to be the a target of neutralizing antibodies and the T cell response [13,40,41]. The goal for including prM in this vaccine construct is to aid in the proper folding of Zika E proteins to allow for the proper folding of E and the presentation of neutralizing antibody epitopes, leading to a strong antibody response that has been shown in other similar vaccine constructs [60,61].…”

Section: Discussionmentioning

confidence: 99%

“…The presence of these three structural proteins on the virus surface make them all possible antibody epitopes. Studies done to map the antibody response to ZIKV have shown that, similar to other flaviviruses, the bulk of the antibody response is directed toward the E protein [39][40][41]. Additionally, evidence from natural history studies indicate that ZIKV E stimulates both a T cell and antibody response in humans [42][43][44][45][46].…”

mentioning

confidence: 99%

Immunogenicity and Efficacy of a Recombinant Human Adenovirus Type 5 Vaccine against Zika Virus

et al. 2020

View full text Add to dashboard Cite

Zika virus (ZIKV) is a significant public health concern due to the pathogen's ability to be transmitted by either mosquito bite or sexual transmission, allowing spread to occur throughout the world. The potential consequences of ZIKV infection to human health, specifically neonates, necessitates the development of a safe and effective Zika virus vaccine. Here, we developed an intranasal Zika vaccine based upon the replication-deficient human adenovirus serotype 5 (hAd5) expressing ZIKV pre-membrane and envelope protein (hAd5-ZKV). The hAd5-ZKV vaccine is able to induce both cell-mediated and humoral immune responses to ZIKV epitopes. Importantly, this vaccine generated CD8 + T cells specific for a dominant ZIKV T cell epitope and is shown to be protective against a ZIKV challenge by using a pre-clinical model of ZIKV disease. We also demonstrate that the vaccine expresses pre-membrane and envelope protein in a confirmation recognized by ZIKV experienced individuals. Our studies demonstrate that this adenovirus-based vaccine expressing ZIKV proteins is immunogenic and protective in mice, and it encodes ZIKV proteins in a conformation recognized by the human antibody repertoire.The development of a ZIKV vaccine is urgent due to the speed of ZIKV spread in susceptible populations, as well as the range of diseases caused by infection [5]. According to the World Health Organization (WHO), a majority of individuals who are infected with ZIKV are asymptomatic, but those with a mild clinical form of the disease report symptoms including fever, rash, conjunctivitis, and muscle and joint pain, all of which typically last less than a week. While these symptoms are rarely debilitating, complications of Zika virus disease can include Guillain-Barré syndrome. Zika-induced microcephaly and congenital abnormalities are generally classified as congenital Zika syndrome (CZS), which is also a potential complication in the developing fetuses of pregnant women [4,6-10]. These risks, combined with the explosive outbreaks that occurred at Yap Island in 2007 [11], French Polynesia in 2013 [12], and Brazil in 2015-16 [13], underscore the need to control the spread of ZIKV. However, there are no current FDA-approved vaccines available to control infection.Harnessing the power of both arms of the adaptive immune response improves vaccine potency and efficacy while reducing opportunities of viral escape. Current data from both naturally acquired human infection and mouse models of ZIKV disease indicate that protection from disease is multi-faceted (reviewed in [14][15][16][17][18]). Both small and large animal models of ZIKV infection have demonstrated that the Zika-specific CD8 + and CD4 + T cell response is necessary and sufficient to protect against a lethal ZIKV challenge [19][20][21][22]. As has been demonstrated previously for multiple flavivirus infections [23-25], ZIKV-specific polyclonal and monoclonal neutralizing antibody responses can protect mice and nonhuman primates from mortality and severe disease. There is also a role fo...

show abstract

Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika

Cited by 50 publications

References 64 publications

Time elapsed between Zika and dengue virus infections affects antibody and T cell responses

Time elapsed between Zika and dengue virus infections affects antibody and T cell responses

B Cell Responses: Cell Interaction Dynamics and Decisions

Immunogenicity and Efficacy of a Recombinant Human Adenovirus Type 5 Vaccine against Zika Virus

Contact Info

Product

Resources

About